Announcements
- Immatics Announces First Quarter 2024 Financial Results and Business Update
- Immatics Announces Full Year 2023 Financial Results and Corporate Update
- Immatics Announces Pricing of $175 Million Public Offering
- Immatics Announces Proposed Public Offering
- Immatics Announces Third Quarter 2023 Financial Results and Business Update
- Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
- Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
- Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
- Moderna und Immatics geben strategische Multi-Plattform-Kollaboration zur Entwicklung innovativer Onkologie Therapeutika bekannt
- Immatics veröffentlicht Ergebnisse des zweiten Quartals 2023 sowie ein Update zur Geschäftsentwicklung
More ▼
Key statistics
On Tuesday, Immatics NV (4A3:MUN) closed at 11.12, -10.61% below its 52-week high of 12.44, set on Jun 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.50 |
---|---|
High | 11.50 |
Low | 11.12 |
Bid | -- |
Offer | -- |
Previous close | 11.12 |
Average volume | 235.00 |
---|---|
Shares outstanding | 103.05m |
Free float | 68.51m |
P/E (TTM) | -- |
Market cap | 1.26bn USD |
EPS (TTM) | -1.05 USD |
Data delayed at least 15 minutes, as of Jun 25 2024 07:13 BST.
More ▼